Back to top
more

Omeros (OMER)

(Real Time Quote from BATS)

$3.32 USD

3.32
81,778

0.00 (0.00%)

Updated May 31, 2024 01:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for OMER

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Omeros Corporation [OMER]

Reports for Purchase

Showing records 321 - 340 ( 423 total )

Company: Omeros Corporation

Industry: Medical - Products

Record: 321

11/09/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of November

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 322

11/05/2012

Daily Note

Pages: 7

OMS302 Second Ph3 Positive; With NDA Filing in H1:13, We See Approval in Late ''13-14; We See Buying Opportunity In Front Of OMS103HP Ph3 Data By YE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 323

10/26/2012

Daily Note

Pages: 6

Q4 Catalysts Timing Update--We Now Estimate OMS302 Phase 3 Top Line Data Release in early November Followed By OMS103HP Before Year-End.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 324

10/05/2012

Industry Report

Pages: 5

LIFE SCIENCES - The Week Ahead in Life Sciences - Upcoming Events for the Week of October 7

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 325

10/03/2012

Daily Note

Pages: 6

Q4 Catalysts Timing Update

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 326

10/02/2012

Daily Note

Pages: 6

Lead PDE-10 Treatment Candidate OMS824 for Potential Blockbuster Indications of Schizophrenia and Cognitive Diseases Going Into the Clinic

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 327

09/19/2012

Daily Note

Pages: 6

NIMH Grant Provides Non-Dilutive Funding To Develop GPCR Antibody Treatments For Neurological Diseases; Reiterate OUTPERFORM and $19 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 328

08/30/2012

Industry Report

Pages: 20

September and Remaining 2012 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 329

08/15/2012

Industry Report

Pages: 24

Life Sciences MAC Best Ideas Conference - New York City - August 14 & 15, 2012 Day 1 Key Takeaways

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 330

08/08/2012

Daily Note

Pages: 6

OMS103HP Phase 3 Trial Completes Patient Enrollment; On Track For Major Catalyst With H2 Data Release; Reiterate OUTPERFORM and $19 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 331

08/07/2012

Company Report

Pages: 8

Q2 Financials a Non-Event. We Project Cash Runway Well Through Transformational H2 Catalysts. Reiterate OUTPERFORM and $19 FV.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 332

08/06/2012

Industry Report

Pages: 17

August and Remaining 2012 Catalysts for Emerging Pharmaceuticals.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 333

07/31/2012

Daily Note

Pages: 6

Omeros Makes Important Discovery in MASP-2 Program Which Could Lead to Improved Therapies for Inflammatory Disorders

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 334

07/19/2012

Company Report

Pages: 3

We are terminating coverage of Omeros Corp due to the departure from the firm of covering analyst

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 335

07/18/2012

Daily Note

Pages: 8

OMS824 Entering The Clinic

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 336

07/06/2012

Industry Report

Pages: 17

Emerging Pharmaceuticals - July and Remaining 2012 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 337

06/29/2012

Company Report

Pages: 3

We are placing Omeros Corp under review due to the departure from the firm of covering analyst

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 338

06/27/2012

Company Report

Pages: 8

We Calculate Follow-On Offering Extends Cash Runway Into 2013; Maintaining OUTPERFORM but Reducing FV to $18 For Dilution

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 339

06/27/2012

Company Report

Pages: 8

We Calculate Follow-On Offering Extends Cash Runway Into 2013; Maintaining OUTPERFORM but Reducing FV to $18 For Dilution

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Omeros Corporation

Industry: Medical - Products

Record: 340

06/27/2012

Daily Note

Pages: 3

Capital Raised

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party